We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




PET Systems Receive ISO Certification and CE Marking

By HospiMedica International staff writers
Posted on 27 Aug 2012
Positron Corporation (Westmont, IL, USA), a leading molecular imaging healthcare company, announced that Neusoft Positron Medical Systems Co., Ltd., has received ISO certification (9001:2008 & 13485:2003) and the CE Marking for their Attrius PET Systems. More...
Neusoft Positron Medical Systems is a joint venture between Neusoft Medical Systems Co., Ltd., and Positron Corporation for the development and manufacturing of Positron Emission Tomography (PET) systems, based in Shenyang (China).

The CE Mark designation, a mandatory conformity marking for products placed on the market in the European Economic Area (EEA), will allow Positron Corporation to market, distribute, and service the Attrius to the EU and other countries that recognize the CE Marking. At present, the contracting parties to the EEA are the EU and its 27 member States, as well as, the 3 EEA/EFTA States.

The ISO 9001:2008 certification specifies requirements for a quality management system where an organization needs to demonstrate its ability to consistently provide product that meets customer and applicable statutory and regulatory requirements, and aims to enhance customer satisfaction through the effective application of the system, including processes for continual improvement of the system and the assurance of conformity to customer and applicable statutory and regulatory requirements.

The ISO 13485:2003 certification specifies requirements for a quality management system where an organization needs to demonstrate its ability to provide medical devices and related services that consistently meet customer requirements and regulatory requirements applicable to medical devices and related services. The primary objective of ISO 13485:2003 is to facilitate harmonized medical device regulatory requirements for quality management systems.

Neusoft Positron Medical Systems Co., Ltd., has stated that it has established and applies a quality management system and management system for medical devices in design and development, manufacture, distribution and service of PET Scanners.

Positron Corporation is a molecular imaging company vertically integrating all the segments of nuclear cardiology. Through proprietary PET imaging systems, radiopharmaceuticals, and radioisotopes solutions, Positron enables healthcare providers to more accurately diagnose disease and improve patient outcomes, while practicing cost effective medicine.

Related Links:

Positron



Gold Member
12-Channel ECG
CM1200B
Biochip Array Technology
Evidence MultiSTAT Drugs of Abuse Urine Multiplex Panel
Pediatric Mask
Respire SOFT
Creatinine/eGFR Meter
StatSensor® Creatinine/eGFR Meter
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Surgical Techniques

view channel
Image Cedit: Shutterstock

New Light-Activated Platform Advances Glioblastoma Surgery and Postoperative Treatment

Glioblastoma, an aggressive primary brain tumor, infiltrates healthy tissue and resists complete surgical removal. Residual microscopic disease and the blood–brain barrier limit the effectiveness of adjuvant... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.